Table 2 Changes in the DDC of bid-winning drugs before and after the implementation of the centralized procurement policy

Second

24/4/2020

acarbose tablets

50mg/30

12.9

2.95

1.09

50mg/45

1.08

1.07

100mg/30

9.74

4.37

0.93

glimepiride tablets

1mg/30

0.1

0.1

1mg/60

0.1

0.1

2mg/30

1.4

0.16

0.09

2mg/60

0.09

0.08

Third

15/11/2020

metformin hydrochloride extended-release tablets

0.5g/60

0.35

0.34

metformin hydrochloride tablets

0.5g/36

0.26

0.26

vildagliptin tablets

50mg/20

1.93

50mg/30

1.9

1.87

Forth

1/5/2021

repaglinide tablets

1mg/30

2.3

1.42

1.41

1mg/60

1.38

1.38

gliclazide extended-release tablets

30mg/60

1.22

1.22

canagliflozin tablets

0.1g/30

3.53

3.53

nateglinide tablets

60mg/24

3.6

3.6

60mg/36

3.55

3.55

empagliflozin tablets

10mg/10

1.84

1.84

25mg/14

1.47

Fifth

15/11/2021

glipizide tablets

5mg/48

0.62

0.32

0.32

glipizide controlled-release tablets

5mg/14

1.98

1.98

miglitol tablets

50mg/30

10.76

8.7

8.7

saxagliptin tablets

5mg/7

2.96

2.96